14,329 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Purchased by Advisors Preferred LLC

Advisors Preferred LLC bought a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 14,329 shares of the biotechnology company's stock, valued at approximately $953,000.

Other large investors have also recently added to or reduced their stakes in the company. Merit Financial Group LLC purchased a new stake in shares of BioMarin Pharmaceutical during the fourth quarter worth approximately $317,000. Assenagon Asset Management S.A. grew its holdings in BioMarin Pharmaceutical by 461.3% during the 4th quarter. Assenagon Asset Management S.A. now owns 611,667 shares of the biotechnology company's stock worth $40,205,000 after acquiring an additional 502,695 shares in the last quarter. Wedmont Private Capital purchased a new stake in shares of BioMarin Pharmaceutical in the 4th quarter valued at approximately $430,000. Swedbank AB raised its holdings in shares of BioMarin Pharmaceutical by 11.2% in the 4th quarter. Swedbank AB now owns 432,122 shares of the biotechnology company's stock valued at $28,403,000 after purchasing an additional 43,593 shares in the last quarter. Finally, EULAV Asset Management raised its holdings in shares of BioMarin Pharmaceutical by 12.9% in the 3rd quarter. EULAV Asset Management now owns 131,000 shares of the biotechnology company's stock valued at $9,208,000 after purchasing an additional 15,000 shares in the last quarter. 98.71% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on BMRN shares. Evercore ISI dropped their target price on BioMarin Pharmaceutical from $115.00 to $105.00 and set an "outperform" rating on the stock in a report on Wednesday, October 30th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $90.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, December 12th. Wolfe Research initiated coverage on BioMarin Pharmaceutical in a research report on Friday, November 15th. They set an "outperform" rating and a $95.00 target price on the stock. William Blair downgraded BioMarin Pharmaceutical from an "outperform" rating to a "market perform" rating in a report on Wednesday, October 30th. Finally, StockNews.com raised shares of BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a report on Tuesday. Seven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $94.20.

BioMarin Pharmaceutical Stock Performance

Shares of BMRN stock traded up $2.31 during trading hours on Wednesday, reaching $65.86. 1,187,703 shares of the company's stock were exchanged, compared to its average volume of 1,526,225. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.27 and a quick ratio of 2.62. BioMarin Pharmaceutical Inc. has a 1 year low of $60.63 and a 1 year high of $94.85. The company has a market cap of $12.55 billion, a P/E ratio of 39.44, a price-to-earnings-growth ratio of 0.57 and a beta of 0.28. The company's 50 day moving average is $64.95 and its two-hundred day moving average is $71.78.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.